Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MYGN - Myriad Genetics, Inc.


IEX Last Trade
28.32
0   0%

Share volume: 883,549
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$28.32
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 9%
Liquidity 27%
Performance 1%
Company vs Stock growth
vs
Performance
5 Days
0.75%
1 Month
1.87%
3 Months
26.14%
6 Months
31.10%
1 Year
55.49%
2 Year
25.47%
Key data
Stock price
$28.32
P/E Ratio 
-16.58
DAY RANGE
N/A - N/A
EPS 
-$1.78
52 WEEK RANGE
$13.82 - $29.08
52 WEEK CHANGE
$0.57
MARKET CAP 
2.573 B
YIELD 
N/A
SHARES OUTSTANDING 
90.820 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
1.57
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$576,488
AVERAGE 30 VOLUME 
$674,355
Company detail
CEO: R. Bryan Riggsbee
Region: US
Website: http://www.myriad.com/
Employees: 2,656
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.

Recent news